The nuclei were counterstained with hematoxylin blue. Image magnifications are 400×. The percentages of positive nuclear learn more expression of STAT3 and pSTAT3 in benign, intermediate, and malignant soft tissue Tubastatin A tumors were also analyzed. The intermediate tumors expressed 52% nuclear expression for STAT3 while this was 85% in malignant tumors. Nuclear expression of pSTAT3 in intermediate and malignant tumors was 47% and 60% respectively. Nuclear expression

of STAT3 and pSTAT3 were not observed in benign soft tissue tumors. Tables 2 lists and summarize the percentages of expressed STAT3 and pSTAT3 in all tumor groups. Table 2 Expression levels of STAT3 and pSTAT3 in benign, intermediate and malignant human soft tissue tumors.   STAT3 pSTAT3   Cytoplasm n (%) Nucleus n (%) Cytoplasm n (%) Nucleus

n(%)     Mild (+) Moderate (++) Intense(+++)   Mild (+) Moderate (++) Intense(+++) Benign(n = 25) 2(8) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) Intermediate(n = 9) 2(8) 4(44.4) 0(0) 5(55) 3(33.3) 1(11.1) 0(0) 4(44) Malignant(n CX-6258 cell line = 48) 2(8) 7(14.6) 37(77.1) 42(87.5) 7(14.6) 12(25) 5(10.4) 24(50) Immunoblot analysis of STAT3 and pSTAT3 in soft tissue tumors STAT3 and p-STAT3 are constitutively expressed in soft tissue tumors The expression levels of STAT3 and pSTAT3 were analyzed by immunoblotting in representative soft tissue tumor samples [Figure 3]. STAT3 was found to be overexpressed in malignant tumors, when compared with intermediate and benign soft tissue tumors. The malignant tumor samples showed high level expression of pSTAT3 when compared with intermediate and benign soft tissue tumors. The data also revealed that STAT3 and pSTAT3 band intensities correlated selleck kinase inhibitor to immunohistochemistry results. Figure 3 Representative Western blotting analysis of STAT3 and pSTAT3 in soft tissue tumor extracts. Increased expression of STAT3 and pSTAT3 were observed in high and intermediate grade soft tissue tumors compared to benign tumors. Lane 1: malignant soft tissue tumor;

lane 2: intermediate soft tissue tumor; lane 3: benign soft tissue tumor. β-actin was used to verify equal gel loading. Expression of STAT3 at the mRNA level in soft tissue tumors STAT3 gene expression correlates with tumor grade in soft tissue tumors Reverse transcription -PCR was done to analyze the mRNA level expression of STAT3 in representative soft tissue tumor samples [Figure 4]. A high level expression of STAT3 mRNA was observed in tumor samples. Among the tumor samples, STAT3 mRNA was found to be overexpressed in malignant and intermediate tumors when compared with benign soft tissue tumors [Figure 5]. Together these results indicate that fluctuations observed in STAT3 mRNA expression correlated with its protein level expression.